Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Litifilimab in active systemic lupus erythematosus
NCT04961567Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Jul 2021
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of litifilimab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Biogen. Primary endpoint: Systemic Lupus Erythematosus Responder Index of 4 at 52 weeks. Started Jul 2021; status: active, not recruiting.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04961567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961567.